147 related articles for article (PubMed ID: 23689716)
1. MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets.
Steele J; Zhang Q; Beamer G; Butler M; Bowlin T; Tzipori S
Antimicrob Agents Chemother; 2013 Aug; 57(8):4039-41. PubMed ID: 23689716
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets.
Kim HB; Zhang Q; Sun X; Beamer G; Wang Y; Tzipori S
Antimicrob Agents Chemother; 2014 Dec; 58(12):7560-4. PubMed ID: 25267665
[TBL] [Abstract][Full Text] [Related]
3. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.
Butler MM; Shinabarger DL; Citron DM; Kelly CP; Dvoskin S; Wright GE; Feng H; Tzipori S; Bowlin TL
Antimicrob Agents Chemother; 2012 Sep; 56(9):4786-92. PubMed ID: 22733075
[TBL] [Abstract][Full Text] [Related]
4. Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment.
Li Y; Figler RA; Kolling G; Bracken TC; Rieger J; Stevenson RW; Linden J; Guerrant RL; Warren CA
BMC Infect Dis; 2012 Dec; 12():342. PubMed ID: 23217055
[TBL] [Abstract][Full Text] [Related]
5. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
[TBL] [Abstract][Full Text] [Related]
6. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
[TBL] [Abstract][Full Text] [Related]
7. Plasmid Acquisition Alters Vancomycin Susceptibility in Clostridioides difficile.
Pu M; Cho JM; Cunningham SA; Behera GK; Becker S; Amjad T; Greenwood-Quaintance KE; Mendes-Soares H; Jones-Hall Y; Jeraldo PR; Chen J; Dunny G; Patel R; Kashyap PC
Gastroenterology; 2021 Feb; 160(3):941-945.e8. PubMed ID: 33197449
[TBL] [Abstract][Full Text] [Related]
8. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
[TBL] [Abstract][Full Text] [Related]
10. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
11. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.
Weiss K; Allgren RL; Sellers S
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S110-5. PubMed ID: 22752858
[TBL] [Abstract][Full Text] [Related]
12. A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea.
Abad CLR; Safdar N
Gastroenterol Clin North Am; 2021 Jun; 50(2):323-340. PubMed ID: 34024444
[TBL] [Abstract][Full Text] [Related]
13. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.
Abujamel T; Cadnum JL; Jury LA; Sunkesula VC; Kundrapu S; Jump RL; Stintzi AC; Donskey CJ
PLoS One; 2013; 8(10):e76269. PubMed ID: 24098459
[TBL] [Abstract][Full Text] [Related]
14. Anti-virulence strategies for
Stewart D; Anwar F; Vedantam G
Gut Microbes; 2020 Nov; 12(1):1802865. PubMed ID: 33092487
[No Abstract] [Full Text] [Related]
15. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS
Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229
[TBL] [Abstract][Full Text] [Related]
16. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
17. Effects of β-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea.
Knecht H; Neulinger SC; Heinsen FA; Knecht C; Schilhabel A; Schmitz RA; Zimmermann A; dos Santos VM; Ferrer M; Rosenstiel PC; Schreiber S; Friedrichs AK; Ott SJ
PLoS One; 2014; 9(2):e89417. PubMed ID: 24586762
[TBL] [Abstract][Full Text] [Related]
18. Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection.
Bossé D; Lemire C; Ruel J; Cantin AM; Ménard F; Valiquette L
Infection; 2013 Apr; 41(2):579-82. PubMed ID: 22996384
[TBL] [Abstract][Full Text] [Related]
19. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection.
Abutaleb NS; Seleem MN
Sci Rep; 2020 May; 10(1):7701. PubMed ID: 32382070
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Chicken IgY Specific to
Pizarro-Guajardo M; Díaz-González F; Álvarez-Lobos M; Paredes-Sabja D
Front Cell Infect Microbiol; 2017; 7():365. PubMed ID: 28856119
[No Abstract] [Full Text] [Related]
[Next] [New Search]
